|
End-of-day quote
Korea S.E.
14/08/2026
|
5-day change | 1st Jan Change | ||
| 201,000.00 KRW | -0.50% |
|
+0.85% | +16.60% |
| 08-04 | Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma | MT |
| 07-24 | Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- A068270 Stock
- Consensus Celltrion, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
